Workflow
基蛋生物科技股份有限公司关于公司涉及诉讼的进展公告

Core Viewpoint - The lawsuit involving基蛋生物科技股份有限公司 (the Company) against its subsidiary, 武汉景川诊断技术股份有限公司 (景川诊断), has reached a final judgment, which is not expected to impact the Company's current or future profits [2][11]. Group 1: Lawsuit Background - The Company, as the controlling shareholder of 景川诊断, initiated a lawsuit due to difficulties in communication regarding the operational status and financial data of 景川诊断, which hindered internal audits [3]. - The lawsuit was filed in the Wuhan East Lake New Technology Development Zone People's Court [3]. Group 2: Legal Proceedings - The Company requested the court to order 景川诊断 to provide various corporate documents and financial reports from July 21, 2020, until the date of actual review [4]. - The first-instance judgment mandated 景川诊断 to provide the requested documents within ten days, while other requests from the Company were dismissed [5][6]. - 景川诊断 appealed the first-instance judgment, seeking to overturn the ruling and have the Company bear all litigation costs [7]. Group 3: Final Judgment - The second-instance court upheld the original ruling, dismissing the appeal from 景川诊断 and maintaining the requirement for document provision [8][9]. - The appeal cost of 100 yuan will be borne by 景川诊断 [8]. Group 4: Impact on Company - The final judgment is not expected to affect the Company's current or future profits, as it does not involve a specific monetary claim [2][11].